Company news
Traws Pharma, Inc. (NASDAQ:TRAW) news
Traws Pharma, Inc. news releases on 6ix. Latest, Aug 14, 2026: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
Press releases & updates
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
August 14, 2026
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
June 21, 2026
Traws Pharma Provides Regulatory Update on Influenza Program
June 12, 2026
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
May 26, 2026
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
May 15, 2026
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
May 8, 2026
Traws Pharma Announces Up to $60 Million Private Placement Financing
April 14, 2026
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
February 19, 2026
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
January 26, 2026
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
January 13, 2026
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
December 22, 2025
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
December 17, 2025
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
November 13, 2025
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
October 30, 2025
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
October 22, 2025
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
October 14, 2025
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
October 6, 2025
Annovis Appoints Mark Guerin as Chief Financial Officer
September 25, 2025
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
August 18, 2025
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
August 14, 2025
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
August 8, 2025
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
June 30, 2025
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
June 3, 2025
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
May 27, 2025
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
May 15, 2025
Traws Pharma Reports Full Year 2024 Results and Business Highlights
March 31, 2025
Traws Pharma Announces Management Updates
March 28, 2025
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
March 26, 2025
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
March 25, 2025
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates
March 24, 2025
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
March 21, 2025
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
March 3, 2025
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
February 28, 2025
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
January 22, 2025
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
January 9, 2025
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
December 29, 2024
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
December 22, 2024
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
November 13, 2024
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
October 7, 2024
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
September 29, 2024
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
September 19, 2024
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
September 16, 2024
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
August 14, 2024
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
August 13, 2024
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
May 22, 2024
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
May 6, 2024
Traws Pharma Announces New Employee Inducement Grants
April 1, 2024
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
April 1, 2024
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
March 7, 2024